REGENERON PHARMACEUTICALS, INC.
REGNAPI behind this page
REGN FY 2025 request
Playground key active
/api/financials?ticker=REGN&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 14,342.9 | 14,202 | +1.0% |
Show Product Lines breakouts |
|||
| Collaboration revenue | 7,331.2 | 6,057.8 | +21.0% |
| ELYEA HD And EYLEA · US | 4,384.7 | 5,968.2 | -26.5% |
| ELYEA HD · US | 1,636.9 | 1,201.1 | +36.3% |
| Evkeeza · US | 162.2 | 125.7 | +29.0% |
| EYLEA · US | 2,747.8 | 4,767.1 | -42.4% |
| Inmazeb · US | 37.4 | 76.8 | -51.3% |
| Libtayo | 1,452.2 | 1,216.8 | +19.3% |
| Libtayo · Non Us | 507.5 | 429.5 | +18.2% |
| Libtayo · US | 944.7 | 787.3 | +20.0% |
| Other products | 10.1 | — | — |
| Praluent · US | 262.5 | 241.7 | +8.6% |
| Product | 6,309.1 | 7,629.2 | -17.3% |
| Product And Service Other | 702.6 | 515 | +36.4% |
| Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses · Non Us | -20 | -48.5 | +58.8% |
| Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses · Sanofi Collaboration Agreement, Antibody | -69.5 | -46.8 | -48.5% |
| Regeneron's share of profits · Non Us | 1,282.7 | 1,403.3 | -8.6% |
| Regeneron's share of profits · Sanofi Collaboration Agreement, Antibody | 5,241.6 | 3,923.5 | +33.6% |
| Reimbursement for manufacturing of commercial supplies · Non Us | 139.7 | 95.7 | +46.0% |
| Reimbursement for manufacturing of commercial supplies · Sanofi Collaboration Agreement, Antibody | 642.4 | 607.9 | +5.7% |
| Reimbursement of commercialization-related expenses · Sanofi Collaboration Agreement, Antibody | 729.3 | 655.4 | +11.3% |
| Research & Development | 5,850.2 | 5,132 | +14.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 5,850.2 | 5,132 | +14.0% |
| Reportable Segment · Clinical manufacturing costs | 1,391.2 | 1,195.9 | +16.3% |
| Reportable Segment · Direct research and development expenses | 1,758.1 | 1,588.8 | +10.7% |
| Reportable Segment · Indirect research and development expenses | 258.2 | 241.5 | +6.9% |
| Reportable Segment · Indirect research and development expenses | 635.4 | 614.9 | +3.3% |
| Reportable Segment · Indirect research and development expenses | 1,800.8 | 1,681.7 | +7.1% |
| Reportable Segment · Indirect research and development expenses | 2,694.4 | 2,538.1 | +6.2% |
| Reportable Segment · Priority Review Voucher | 155 | — | — |
| Acquired In Process Research And Development | 124.1 | 101 | +22.9% |
| Selling, General & Administrative | 2,700 | 2,954.4 | -8.6% |
| Cost of Revenue (FY) | — | — | — |
Show Product Lines breakouts |
|||
| Cost of collaboration and contract manufacturing | 959.9 | 883.2 | +8.7% |
| Product | 1,140.8 | 1,087.3 | +4.9% |
| Other Operating Income Expense Net | -10 | 53.4 | -118.7% |
| Total Costs & Expenses | 10,765 | 10,211.3 | +5.4% |
| Operating Income | 3,577.9 | 3,990.7 | -10.3% |
| Other Non-Operating Income (Expense) | 1,696.6 | 844.4 | +100.9% |
| Interest Expense | -43.8 | -55.2 | +20.7% |
| Non-Operating Income (Expense) | 1,652.8 | 789.2 | +109.4% |
| Income Before Taxes | 5,230.7 | 4,779.9 | +9.4% |
| Income Tax Expense (Benefit) | 725.8 | 367.3 | +97.6% |
| Net Income | 4,504.9 | 4,412.6 | +2.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 4,504.9 | 4,412.6 | +2.1% |
| EPS (Basic) | 43.07 | 40.9 | +5.3% |
| EPS (Diluted) | 41.48 | 38.34 | +8.2% |
| Wtd Avg Shares (Basic) | 104.6 | 107.9 | -3.1% |
| Wtd Avg Shares (Diluted) | 108.6 | 115.1 | -5.6% |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 83 | 73.6 | +12.8% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 2.4 | -0.6 | +500.0% |
| Comprehensive Income | 4,590.3 | 4,485.6 | +2.3% |
| Other Comprehensive Income | 85.4 | 73 | +17.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 85.4 | 73 | +17.0% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 3,118.1 | 2,488.2 | +25.3% |
| Marketable Securities (Current) | 5,487.1 | 6,524.3 | -15.9% |
| Accounts Receivable | 5,741.1 | 6,211.9 | -7.6% |
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts |
|||
| Trade Accounts Receivable | 3.46 | 4.28 | -19.2% |
Show Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project breakouts |
|||
| Bayer | 287.6 | 349.9 | -17.8% |
| Sanofi Collaboration Agreement, Antibody | 1,610.6 | 1,216.2 | +32.4% |
| Inventory | 3,200.8 | 3,087.3 | +3.7% |
| Prepaid Expenses & Other Current Assets | 474.8 | 349.2 | +36.0% |
| Total Current Assets | 18,021.9 | 18,660.9 | -3.4% |
| Non-Current Assets | |||
| Marketable Securities (Non-Current) | 10,260.6 | 8,900.1 | +15.3% |
| Deferred Tax Assets | 4,077.2 | 3,314.1 | +23.0% |
| Other Non-Current Assets | 1,821.2 | 1,136 | +60.3% |
| Total Assets | 40,558.7 | 37,759.4 | +7.4% |
| Operating Lease Right-of-Use Assets | 245.8 | 217.4 | +13.1% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Acquired product rights - Libtayo | 1,203.4 | 1,093.4 | +10.1% |
| Other Intangible Assets | 1.2 | 2.4 | -50.0% |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 5,120.4 | 4,599.7 | +11.3% |
Show Geography breakouts |
|||
| Non Us | 788 | 715.9 | +10.1% |
| US | 4.33 | 3.88 | +11.5% |
| Intangible Assets Net Excluding Goodwill | 1,257.4 | 1,148.6 | +9.5% |
| Current Liabilities | |||
| Accounts Payable | 939 | 789.5 | +18.9% |
| Accrued Liabilities And Other Liabilities | 2,876.4 | 2,527.1 | +13.8% |
| Deferred Revenue (Current) | 553 | 627.7 | -11.9% |
| Total Current Liabilities | 4,368.4 | 3,944.3 | +10.8% |
| Non-Current Liabilities | |||
| Long-Term Debt | 1,985.9 | 1,984.4 | +0.1% |
| Finance Lease Liability Noncurrent | 720 | 720 | 0.0% |
| Contract With Customer Liability Noncurrent | 208.7 | 185.7 | +12.4% |
| Other Non-Current Liabilities | 2,018.8 | 1,571.4 | +28.5% |
| Total Liabilities | 9,301.8 | 8,405.8 | +10.7% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 1.750% Senior Notes due September 2030 · Senior Notes | 1,244.5 | 1,243.3 | +0.1% |
| 2.800% Senior Notes due September 2050 · Senior Notes | 741.4 | 741.1 | 0.0% |
Show Long-Term Debt Type breakouts |
|||
| Senior Notes | 1,985.9 | 1,984.4 | +0.1% |
| Operating Lease Liabilities | 229 | 204.1 | +12.2% |
| Stockholders' Equity | |||
| Common Stock (Q) | — | — | — |
Show Statement Class Of Stock breakouts |
|||
| Common Stock | 0.1 | 0.1 | 0.0% |
| Additional Paid-In Capital | 13,995 | 12,855.9 | +8.9% |
| Retained Earnings | 35,797.1 | 31,672.9 | +13.0% |
| Accumulated Other Comprehensive Income | 77.5 | -7.9 | +1081.0% |
| Treasury Stock Common Value | -18,612.8 | -15,167.4 | -22.7% |
| Total Stockholders' Equity | 31,256.9 | 29,353.6 | +6.5% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 77.5 | -7.9 | +1081.0% |
| Additional Paid In Capital | 13,995 | 12,855.9 | +8.9% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 35,797.1 | 31,672.9 | +13.0% |
| Treasury Stock Common | -18,612.8 | -15,167.4 | -22.7% |
| Total Liabilities & Equity | 40,558.7 | 37,759.4 | +7.4% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 543.7 | 482.9 | +12.6% |
| Stock-Based Compensation | 993.7 | 982.8 | +1.1% |
| Marketable And Other Securities Gain Loss | -946.1 | -118.3 | -699.7% |
| Other Non-Cash Items | 135.5 | 36.1 | +275.3% |
| Increase Decrease In Deferred Income Taxes | -785.4 | -757.3 | -3.7% |
| Change in Accounts Receivable | 498.1 | -554 | +189.9% |
| Change in Inventory | -275.3 | -619.7 | +55.6% |
| Change in Prepaid & Other Assets | -375.3 | -407.5 | +7.9% |
| Change in Deferred Revenue | -51.7 | 227.8 | -122.7% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 736.8 | 735.1 | +0.2% |
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | 474 | 7.9 | +5900.0% |
| Net Cash from Operations | 4,978.9 | 4,420.5 | +12.6% |
| Deferred Income Taxes | -785.4 | -757.3 | -3.7% |
| Investing Activities | |||
| Payments To Acquire Marketable Securities | -10,958.3 | -16,617.4 | +34.1% |
| Proceeds From Sale And Maturity Of Marketable Securities | 11,546.2 | 15,027.3 | -23.2% |
| Payments To Acquire Productive Assets | -898.4 | -755.9 | -18.9% |
| Payments To Acquire Intangible Assets1 | -315.3 | -125.7 | -150.8% |
| Payments To Acquire Businesses Net Of Cash Acquired | -3.3 | -16.5 | +80.0% |
| Net Cash from Investing | -629.1 | -2,468.1 | +74.5% |
| Financing Activities | |||
| Proceeds From Issuance Of Common Stock | 635.9 | 1,465.3 | -56.6% |
| Tax Withholding for Share Compensation | -532.1 | -1,029.1 | +48.3% |
| Share Repurchases | -3,438.6 | -2,603.3 | -32.1% |
| Payments Of Dividends | -370.3 | — | — |
| Proceeds From Payments For Other Financing Activities | -10.3 | -33.4 | +69.2% |
| Net Cash from Financing | -3,715.4 | -2,200.5 | -68.8% |
| Supplemental | |||
| Interest Paid | 41.6 | 52.6 | -20.9% |
| Income Taxes Paid | 1,253 | 743 | +68.6% |
| Unpaid Capital Expenditures | 178.8 | 151.6 | +17.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 0.3 | -0.7 | +142.9% |
| Net Change in Cash | 634.7 | -248.8 | +355.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,123.7 | 2,489 | +25.5% |
Values in millions USD. Source: SEC EDGAR 10-K filing.